FIELD: medicine.
SUBSTANCE: methods of the invention include contacting of an urine sample obtained from an individual with an FRα binding antibody to determine the FRα level, which is not associated with the cell, in the said urine sample, comparing the FRα level not associated with the cell in the said urine sample obtained from the said individual to the FRα level in the control sample, FRα level increase establishment in the said urine sample obtained from the said individual, compared to the FRα level in the control sample, and determination of a FRα-expressing malignant tumour, based on this increase. A kit for ovarian cancer progression assessment contains means for determination of FRα level not associated with the cell in the urine sample and instructions for use.
EFFECT: application of inventions allows to non-invasively diagnose malignant tumours, determine the level of risk of their development and progression.
23 cl, 32 tbl, 20 dwg, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FOLATE RECEPTOR ALPHA AS A DIAGNOSTIC AND PROGNOSTIC MARKER OF MALIGNANT TUMOURS EXPRESSING FOLATE RECEPTOR ALPHA | 2011 |
|
RU2764592C2 |
| ANTIBODIES TO FOLIC ACID RECEPTOR 1, THEIR IMMUNOCONJUGATES AND APPLICATION | 2011 |
|
RU2610663C2 |
| ANTIBODIES AND ANALYSIS METHODS FOR FOLIC ACID 1 RECEPTOR DETECTION | 2014 |
|
RU2725825C2 |
| METHODS OF TREATING LUNG CANCER | 2016 |
|
RU2718780C2 |
| ANTIBODIES AGAINST FOLIC ACID RECEPTOR 1, THEIR IMMUNOCONJUGATES AND USE | 2011 |
|
RU2740479C2 |
| DIAGNOSTIC ASSAYS AND KITS FOR DETECTION OF FOLATE RECEPTOR 1 | 2013 |
|
RU2668824C2 |
| ANTIBODIES TO THE RELATED CANCER-EMBRYONIC ANTIGEN CELL ADHESION MOLECULE (CEACAM) | 2012 |
|
RU2650869C2 |
| ANTIBODY-DRUG CONJUGATES BASED ON ERIBULIN AND APPLICATION METHODS | 2017 |
|
RU2754369C2 |
| AFUCOSYLATED FGFR2IIIB FIBROBLAST GROWTH FACTOR RECEPTOR | 2014 |
|
RU2698061C2 |
| TREATING A MALIGNANT TUMOR USING A CHIMERIC ANTIGEN CD19 RECEPTOR | 2015 |
|
RU2718542C2 |
